U.S. markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
149.45-4.94 (-3.20%)
Al cierre: 04:00PM EDT
144.29 -5.16 (-3.45%)
Fuera de horario: 07:33PM EDT

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200
https://www.alnylam.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo2,100

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Yvonne L. Greenstreet M.B.A., MBChBCEO & Director2.09MN/D1963
Mr. Jeffrey V. Poulton M.B.A.CFO & Executive VP972.35kN/D1968
Dr. Akshay K. Vaishnaw M.D., Ph.D.Chief Innovation Officer & Member of the Scientific Advisory Board1.24M848.93k1963
Dr. Pushkal P. Garg M.D.Chief Medical Officer and Executive VP of Development & Medical Affairs1MN/D1968
Mr. Timothy J. MainesChief Technical Operations & Quality OfficerN/DN/DN/D
Dr. Kevin Joseph Fitzgerald Ph.D.Senior VP, Head of Research & Chief Scientific OfficerN/DN/D1969
Ms. Christine Regan LindenboomSenior VP of Investor Relations & Corporate CommunicationsN/DN/D1981
Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerN/DN/DN/D
Mr. Evan LippmanChief Corporate Development & Strategy OfficerN/DN/DN/D
Ms. Kelley BoucherChief Human Resource OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Alnylam Pharmaceuticals, Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 8; Junta: 2; Derechos del accionista: 6; Compensación: 6.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.